TCI GENE Inc. (TPEX:6879)

Market Cap	932.66M -34.8%
Revenue (ttm)	273.61M -21.3%
Net Income	40.57M -28.0%
EPS	1.52 -28.3%
Shares Out	26.46M
PE Ratio	23.19
Forward PE	n/a
Dividend	2.00 (5.56%)
Ex-Dividend Date	Sep 5, 2025

Volume	13
Average Volume	6,304
Open	34.35
Previous Close	35.25
Day's Range	34.35 - 34.50
52-Week Range	32.45 - 55.80
Beta	0.17
RSI	44.74
Earnings Date	May 13, 2026

About TCI GENE

TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-der...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6879

Financial Performance

In 2025, TCI GENE's revenue was 273.61 million, a decrease of -21.27% compared to the previous year's 347.54 million. Earnings were 40.57 million, a decrease of -27.96%.